Want to see JP:4978 full AI Analyst Report?
4978 Stock Chart & Stats
¥143.00
¥3.00(2.91%)
At close: 4:00 PM EST
¥143.00
¥3.00(2.91%)
Day’s Range― - ―
52-Week Range¥117.00 - ¥204.00
Previous CloseN/A
Volume331.50K
Average Volume (3M)521.11K
Market Cap
¥12.47B
Enterprise Value¥6.25B
Total Cash (Recent Filing)¥5.62B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.59
Shares Outstanding103,943,890
10 Day Avg. Volume587,650
30 Day Avg. Volume521,113
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.88
Price to Sales (P/S)7.46
P/FCF Ratio-34.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.7
Revenue Forecast (FY)¥3.53B
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetAn effectively debt-free balance sheet and a large, stable equity base reduce insolvency and refinancing pressure. This gives ReproCELL more flexibility to fund research, absorb operating volatility, and pursue its cell-technology activities through the next several quarters.
Meaningful Gross ProfitGross profit remained above ¥1.0B in 2026 despite the revenue decline, indicating the core offerings still generate meaningful economic value before operating costs. Preserving this gross-profit base could support recovery if sales stabilize and operating discipline improves.
Human Cell Technology PlatformThe company is positioned in human cell technologies, including iPSC-related products, cell lines, reagents, and contract research services. This offering spans biomedical research, drug discovery, and regenerative-medicine development, creating multiple routes to customer demand.
Bears Say
Revenue ContractionRecent revenue deterioration after earlier growth shows that demand and execution have been inconsistent. A smaller sales base can reduce operating leverage, limit investment capacity, and make it harder for the company to convert its cell-technology platform into predictable growth.
Persistent Cash BurnPersistent negative free cash flow indicates the business has not been self-funding, even when accounting profit briefly improved. Continued cash burn can consume the equity buffer over time and constrain research investment, commercial expansion, and other strategic choices.
Unstable ProfitabilityThe swing from a brief 2025 profit to a sizable 2026 loss demonstrates weak earnings predictability and limited cost absorption. Deeply negative operating profit makes results more dependent on future revenue recovery, while inconsistent returns reduce confidence in sustainable profitability.
4978 FAQ
What was ReproCELL Inc.’s price range in the past 12 months?
ReproCELL Inc. lowest stock price was ¥117.00 and its highest was ¥204.00 in the past 12 months.
What is ReproCELL Inc.’s market cap?
ReproCELL Inc.’s market cap is ¥12.47B.
When is ReproCELL Inc.’s upcoming earnings report date?
ReproCELL Inc.’s upcoming earnings report date is Nov 12, 2026 which is in 19 days.
How were ReproCELL Inc.’s earnings last quarter?
ReproCELL Inc. released its earnings results on Aug 13, 2026. The company reported -¥1.56 earnings per share for the quarter.
Is ReproCELL Inc. overvalued?
According to Wall Street analysts ReproCELL Inc.’s price is currently Overvalued.
Does ReproCELL Inc. pay dividends?
ReproCELL Inc. does not currently pay dividends.
What is ReproCELL Inc.’s EPS estimate?
ReproCELL Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ReproCELL Inc. have?
ReproCELL Inc. has 103,943,890 shares outstanding.
What happened to ReproCELL Inc.’s price movement after its last earnings report?
ReproCELL Inc. reported an EPS of -¥1.56 in its last earnings report. Following the earnings report the stock price went up 0.714%.
Which hedge fund is a major shareholder of ReproCELL Inc.?
Currently, no hedge funds are holding shares in JP:4978
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ReproCELL Inc.
Established in 2003 and headquartered in Yokohama, Japan, ReproCELL Incorporated operates as a prominent firm specializing in stem cell research. The company furnishes an extensive portfolio of products crucial for various stem cell applications, including a diverse array of specialized reagents for RNA reprogramming, cell growth (such as small molecules, growth factors, and cytokines), cell characterization (like antibodies and staining kits), cell culture (including pluripotent stem cell media and cell substrates), and cell handling (such as cryopreservation media, dissociation solutions, and transfection reagents). Furthermore, ReproCELL provides differentiated induced pluripotent stem cells (iPSCs), related components like feeder cells and induced neurons, 3D cell culture systems, and general laboratory consumables. Complementing its product lines, the company offers a comprehensive suite of services, spanning preclinical genomics, dedicated stem cell research, drug development support (encompassing efficacy, safety, and ADME analyses), access to human tissue samples, therapeutic pipeline development, and a range of clinical services, including laboratory diagnostics and the creation of GMP iPSC master cell banks.